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Abstract
Bosch, Martina M., Daniel Barthelmes, and Klara Landau. High altitude retinal hemorrhages: an update. High
Alt Med Biol. 13:240–244, 2012. —Retinal hemorrhages represent a common phenomenon in eyes of high altitude
climbers. In this review, we present an update about this entity, with focus on its pathophysiology and practical
implications. Due to their delayed appearance in the course of an expedition, retinal hemorrhages are not
predictive when assessing the risk for life-threatening complications related to hypobaric hypoxia. Consequences
for ocular health depend greatly on the extent and localization of retinal bleedings, but are generally mild and
reversible in healthy eyes.
Introduction
Retinal hemorrhages occur in various diseases, suchas diabetes mellitus, arterial hypertension, retinal vein
occlusion, after Valsalva maneuver, or in leukemia. A com-
mon denominator in these conditions is damage of retinal
vessels, leading to extravasation of blood. Since retinal vessels
are embedded in the neuronal tissue, intraretinal hemor-
rhages appear feathery or flame-shaped, following the anat-
omy of the nerve fiber layer. In cases with larger hemorrhages
or extensive vessel damage, blood may be found on the sur-
face of the retina, trapped between the posterior vitreous
membrane and the retina. Such hemorrhages are well defined
and rather prominent. In cases where the posterior vitreous
face is not adherent to the retinal surface (i.e., after posterior
vitreous detachment), these hemorrhages may be dispersed
into the vitreous cavity.
Depending on size and location, hemorrhages may go
unnoticed if located peripherally of the macula or result in
noticeable scotomas when located close to the fovea centralis
of the retina. Small intraretinal hemorrhages may cause only
slight visual disturbances, whereas a spillover of blood into
the vitreous cavity may cause severe visual impairments—
down to an acuity of counting fingers or less.
Treatment of hemorrhages, especially when not intense, is
not required, as hemorrhages are resorbed within days or
weeks—depending on the size—and usually do not result in
permanent damage to the neural tissue ( Regnault 1970; Maar
et al., 2000).
High Altitude-Associated Retinal Hemorrhages
The retinal hemorrhages described above also occur at high
altitude—initially reported by Houston in 1968 on Mount
Logan. They have been closely associated with high altitude
sickness, as first described by Singh et al. (1969) in 24 of of
1925 subjects staying between 11,000 ft (3353 m) and 18,000 ft
(5486 m), and Frayser et al. (1970) in nine of 25 mountaineers
at an altitude of 17,500 ft (5334 m).
Changes at the posterior segment of the eye can be found in
unacclimatized individuals exposed to hypobaric hypoxia at
high altitudes and have been linked to the complex of alti-
tude-related illness (AI), which also includes acute mountain
sickness (AMS), high altitude cerebral edema (HACE), and
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high altitude pulmonary edema (HAPE) (Houston, 1976;
Meehan and Zavala, 1982; Hackett and Roach, 2001). In-
dependent risk factors for the development of AI are maxi-
mum altitude climbed to, individual susceptibility, and ascent
rate (Schneider et al. 2002; Bloch et al., 2009).
Signs of high altitude retinopathy (HAR) include retinal
hemorrhages (HARH), engorgement and tortuosity of retinal
vessels, optic disc hyperemia and swelling, cotton wool spots,
and even vitreous hemorrhage (Frayser et al., 1970; Rennie
and Morrissey 1975; Shults and Swan 1975; Wiedman 1975;
McFadden et al., 1981). Butler et al. (1992) reported central
retinal vein occlusion in association with altitude retinopathy.
A cotton wool spot is an area where nerve fiber layer infarc-
tion has taken place, which is surrounded by swollen nerve
axons. This is caused by the combination of hypoxia and
hypoperfusion, including further mechanisms such as prob-
able micro-embolization due to platelet aggregates that de-
velop during hypoxia or hypobaria (Gray et al., 1975;
McFadden et al., 1981). A current study on retinal changes in
various altitude diseases found patients with branch retinal
vein occlusions with macular edema (Arora et al., 2011),
possibly caused by increased hematocrit and hemoglobin
concentrations. A classification for HAR has been established
by Wiedman and Tabin (1999). They described four stages
of increasing severity of high altitude retinopathy where the
area of retinal bleeding parallels the occurrence of optic disc
edema.
Possible Causes and Characteristics of High Altitude
Retinal Hemorrhages
High altitude retinal hemorrhages (HARH, Fig. 1) are most
likely induced by systemic hypoxic effects on the eye, despite
regulatory adjustments by both retinal and choroidal circu-
lation. According to data from the Muztagh Ata study in 2005,
increased hematocrit, possibly representing higher blood
viscosity, correlated positively with the number of hemor-
rhages (Barthelmes et al., 2011). Elevated blood viscosity
may increase shear stress to the pre-damaged retinal vascular
endothelial cells.
A subset of climbers show white-centered hemorrhages,
also known as Roth spots (Roth, 1872). This specific type of
bleeding observed at sea-level occurs in patients with capil-
lary fragility due to systemic infections, hypertension, leuke-
mia, diabetes (Rodriguez-Adrian et al., 2003), anemia, and
leukemia, (Wechsler et al., 2004)—all of which may eventually
result in capillary rupture (Ling and James, 1998). The white
center of a Roth spot has been shown to represent a fibrin-
platelet thrombus. Duane et al. (1980) described this white
thrombus located at the site of a vessel rupture. Duane et al.
(1980) and McFadden et al.(1981) reported Roth spots in
climbers after exposure to high altitudes. High altitude
climbers with Roth spots often present with larger retinal
hemorrhages compared to climbers without white-centered
hemorrhages (Barthelmes et al., 2011). This may be explained
by distinct pathophysiological processes where climbers with
Roth spots have undergone longer episodes of lower oxygen
saturation during the climb (Barthelmes et al., 2011). This
supports the hypothesis that hypoxic damage to retinal ves-
sels at high altitudes can cause wall rupture after a certain
time lag and then induce retinal bleeding, which is also an
explanation for the above-mentioned white-centered hemor-
rhages (Ling and James, 1998).
Which Residual Problems Have Been Documented
after HARH?
Similar to retinal hemorrhages occurring at sea level for
various reasons, high altitude retinal hemorrhages usually
disappear within days or a few weeks without sequelae. The
large scale Muztagh Ata study found no persistent retinal
pathologies 4.5 months after descent (Barthelmes et al., 2011).
Other reports on HARH however mentioned residual prob-
lems as persistent scotomas (Shults and Swan, 1975; McFad-
den et al., 1981), vision loss after ischemic central retinal vein
occlusion (Butler et al., 1992), and visual field shrinkage
(Wiedman, 1975). It seems that in these cases, other patholo-
gies (i.e., vessel occlusions) caused permanent damage rather
than the hemorrhages themselves.
Incidence, Timing and Location of HARH
High altitude retinal hemorrhages can usually be seen ca.
3500 m above sea level (Hackett and Rennie, 1979; Honigman
et al., 2001). Yet, to date, the exact incidence of high altitude
retinal hemorrhages remains uncertain. The estimated inci-
dence of HARH is reported to vary from 0% (Wiedman, 1975)
to 79% (Barthelmes et al., 2011). Since many climbers with
HARH do not experience visual disturbances, small hemor-
rhages, which appear and clear up during the course of the
sojourn at high altitudes, may go unnoticed. Moreover, due to
a time lag between reaching a certain altitude and occurrence
of bleeding, diagnosis of HARH and identification of time of
FIG. 1. This fundus photograph shows the retina of a high
altitude climber at 6870 m, who participated in the Muztagh
Ata study in 2005. To be seen are (A) peripapillary hemor-
rhages, (B, C) retinal hemorrhages at the temporal retinal
vessels, (D) a white-centered hemorrhage (Roth spot) within
the macular region, and (A) early signs of optic disc swelling
(Schnetzler et al., 2006).
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occurrence may only be established by systematic field ex-
aminations at different heights. It is of note that independent
of the amount of hypoxia, a large number of retinal hemor-
rhages were detected shortly after descent from higher alti-
tude, not during the ascent. That is, high altitude retinal
hemorrhages mostly occur after the body has been subjected
to the highest lack of oxygen to the tissue during the climb and
not in a timely manner during or directly afterwards. Most
entities of altitude-related illness occur at the highest reached
altitude and regress after having reached lower altitudes. The
vast majority of HARH were reported to be either near
the optic disc or outside of the temporal retinal arteries (i.e.,
the macula remained unaffected). This explains the lack of
symptoms during a climb in most mountaineers (Barthelmes
et al., 2011).
Climbers, who sustain longer and more extensive systemic
hypoxia during the expedition, present with more HARH
(McFadden et al., 1981; Barthelmes et al., 2011). Also, the
higher the ascent and the longer the duration at high altitudes,
the higher the occurrence of retinal hemorrhages. Further
studies have implicated that HARH may be seen more of-
ten in young and physically well-trained mountaineers—
especially in those who undergo strenuous exercise at high
altitudes (Brinchmann-Hansen et al., 1989; Arora et al.,
2011)—such as in the report by Willmann et al. (2011) where
mountaineers rapidly ascended to an altitude of 4559 m.
To date, there are no correlations between the incidence of
high altitude retinal hemorrhages and medication such as
diuretics or steroids shown in any of the very few high alti-
tude studies considering this issue.
Which Signs and Symptoms of Altitude Illness
Correlate with HAR or Only HARH?
Mountaineers affected by acute mountain sickness (AMS)
suffer from a variety of nonspecific symptoms such as head-
ache, nausea, insomnia, dizziness, lassitude, or fatigue (Roach
et al., 1993). Some show a progression of symptoms eventu-
ally leading to high altitude cerebral edema (HACE), the end-
stage of AMS. Hypoxia-induced increase in cerebral blood
flow coupled with decreased integrity of the blood-brain
barrier and cytotoxic edema are at the center of pathophysi-
ological processes (Wilson et al., 2009). Signs of HACE are
ataxia, altered consciousness, or both in a person with AMS.
This condition is fatal if left untreated promptly and properly.
The cerebral signs of altitude illness are of interest from an
ophthalmological point of view, since the eye is considered to
be ‘‘the window to the brain’’. Regulation of circulation of the
brain has been reported to behave similarly to that of retinal
vessels under hyper- and hypoxic conditions (Delaey and Van
De Voorde 2000; Patton et al., 2005). It is hence possible that
the pathophysiology of AMS, HACE, and retinal changes at
high altitudes possess a common denominator. Studies on
altered autoregulation of the cerebral blood flow ( Jansen
et al., 2002) and vasogenic cerebral edema (Hackett et al.,
1998), possibly causing AMS and HACE, support this
hypothesis.
Whether high altitude retinopathy shows a clear correla-
tion with cerebral dysfunction at high altitude and thus may
be utilized as a predicting sign, is still a matter of debate
(Clarke and Duff, 1976; Wiedman and Tabin, 1999; Bar-
thelmes et al., 2011; Willmann et al., 2011). Hence, we suggest
to discuss HARH separately from optic disc swelling, which
has been included in the current classification of high altitude
retinopathy (Wiedman and Tabin, 1999).
Optic disc swelling has been reported to occur in up to 79%
at altitudes of 4560 m (Willmann et al., 2011) and up to at least
59% of mountaineers at altitudes of 6800 m above sea level,
increasing in incidence with ascent to higher altitudes and
regressing quickly upon descent (Bosch et al., 2008). A cor-
relation between optic disc swelling, peripheral oxygen sat-
uration, and symptoms of acute mountain sickness has been
reported in 27 climbers, concluding that optic disc swelling is
most likely the result of hypoxia-induced brain volume in-
crease (Bosch et al., 2008). On the other hand, Willman et al.
(2011) did not find a correlation between optic disc swelling
and symptoms of acute mountain sickness in 18 mountain-
eers. A possible explanation for this discrepancy is the dif-
ferent ascent profiles (rapid vs. slow) and the different heights
reached in the two studies.
Both optic disc swelling and HARH are signs of overall
susceptibility to hypoxia. But, the dynamics of HARH, as
opposed to those of optic disc swelling, differ as there is a
delay in appearance and a slower regression of changes in the
posterior segment. Clarke and Duff (1976) questioned whe-
ther the appearance of isolated retinal hemorrhages should be
considered a warning sign of impending cerebral edema.
Another study also could not find a correlation between
HARH and cerebral symptoms (Barthelmes et al., 2011).
Wiedman and Tabin (1999), on the other hand, indicated a
possible association between HAR and HACE in their work.
Recommendations
What to do on a trip to high altitude if someone has
symptoms/findings suggestive of HAR?
Symptomatic bleeding in the eye suggests either the
occurrence of hemorrhages within the macula or a spillover
into the vitreous, both of which may impair vision markedly.
If the climber is unfortunate enough to have bilateral hem-
orrhages close to the foveolar region, he or she will have to
descend (with help) since resorption of the blood will take
days to weeks, depending on the hemorrhage. If visual dis-
turbances do not resolve within a week, the climber should
seek consultation by an ophthalmologist within maximally
another week. Since there is no clear evidence that retinal
hemorrhages are warning signs of impending severe acute
mountain sickness or even high altitude cerebral edema,
continuation of the expedition can be ventured—under the
premise that the climber is never alone during the further
sojourn at high altitudes—and only in case visual distur-
bances due to retinal bleeding are minimal and do not impede
the safety of the climb. As soon as scotomas occur in both eyes,
it is prudent to descend immediately and accompanied.
Can people with prior symptomatic retinal
hemorrhages go back to high altitude?
Which guidelines should be followed?
Since HARH are of transient nature, we would not go as
far as to discourage climbers who have experienced prior
symptomatic retinal hemorrhages from going back to high
altitude.
To date there is no medication that has been reported
to prevent retinal hemorrhages. However, studies on high
altitude related diseases are often performed in healthy
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mountaineers who are not on regular medication. Medication
such as nonsteroidal anti-inflammatory drugs, corticoste-
roids, and acetazolamide, were shown to have no impact on
retinal bleeding in the Muztagh Ata study (Barthelmes et al.,
2011).
Future Directions
Further studies with large cohorts and similar ascent pro-
files should be pursued in the future in order to find answers
to current discrepancies in hypotheses concerning the path-
ophysiology of HARH and their association to signs and
symptoms of altitude sickness. More data on the development
of retinal hemorrhages, also in context with optic disc swell-
ing, is needed. Grading of high altitude retinopathy could be
extended to include the fact that changes to the optic disc due
to hypoxia occur more quickly than retinal hemorrhages
during the same hypoxic event. Severity of HAR during a
climb might be defined by emphasizing the appearance of the
optic disc, whereas overall severity after the climb could in-
clude the extent of HARH.
The lack of data regarding how many climbers with pre-
existing medical problems develop high altitude retinal
hemorrhages or whether certain drugs can induce HARH
makes it difficult to develop concise management guide-
lines. Further data should be collected on healthy moun-
taineers taking medication at high altitudes. Thus, the
above-mentioned recommendations should be considered
with caution.
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